EU approves four-in-one Stribild
STOP PRESS: On 28 May 2013, Gilead announced that the European Commission has granted market authorisation for Stribild with an indication for treatment-naive patients.
This is a single tablet combination containing elvitegravir 150 mg/cobicistat 150 mg/FTC 200 mg/tenofovir DF 245 mg.
Ref: Gilead press statement. European Commission approve Stribild, a new single tablet regimen for the treatment of HIV-1 infection. (28 May 2013).